Elite Pharmaceuticals Inc (ELTP)

[bms65]

good read, old article but this will highlight ELTP goal "Over time, it should be a scientific race across the whole pharmaceutical industry to create a market where all opioids have abuse-deterrent properties," said Gary L. Stiles, senior vice president of research and development at the closely held Purdue Pharma.

The race could give a boost to an already lucrative market and raise the cost of pain treatment. A recent Cowen & Co. report predicts an increase in prescription pain drug sales of more than 15% by 2017, reaching $8.4 billion, thanks in part to the FDA ruling. It could also bring about a reshuffling of market share in the fast-growing $7.3 billion pain market, as companies such as Pfizer move with full force in the opioid painkiller market for the first time.

The FDA isn't directly requiring all painkillers to have safeguards. But should an effective abuse-deterrent drug be developed, the FDA said it has the power to remove on-the-market rival products which don't.

Drug companies are racing to conduct the studies and research required by the FDA to prove their drugs thwart abuse. Winning that distinction from the FDA, as Purdue Pharma has done for OxyContin, allows company sales representatives to tout those properties to doctors—forming a potential new marketing battleground for branded drugs. "That's how you're going to see the battle going forward," said Mike Royal